Meetings: Recent Episodes
ReachMD
Host: Marc P. Bonaca, MD, MPH
This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.
Host: Michael E. Yurcheshen, MD, FAASM
Host: Kevin Trice, MD
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Clifford Takemoto, MD
With so many potential therapies emerging for sickle cell disease, where are we with the treatment of adults and children? Dr. Charles Turck joins Dr. Clifford Takemoto, the Chief of the Clinical Division of Hematology at St. Jude Children’s Research Hospital in Memphis, Tennessee, to share therapeutic updates from the 64th Annual American Society of Hematology Meeting.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Namrata Chandhok, MD
Underrepresentation is widespread in hematological clinical trials. To learn more about the challenges preventing representation—and possible solutions—Dr. Charles Turck joins Dr. Namrata Chandhok from the Sylvester Comprehensive Cancer Center at the University of Miami to share insights on inclusion in clinical trials from the American Society of Hematology annual Meeting.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Fatima, Adhi, MD
Guest: Mei Chang, PharmD
Collaborative care is fundamental for critically ill patients, especially when it comes to medication dosing. To explore key considerations on dosing and share insights from their presentations at IDWeek 2022, Dr. Charles Turck is joined by Dr. Adhi Fatima from the Baylor College of Medicine and Mei Chang from the Montefiore Medical Center at the Weiler Division Einstein Campus.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jason Zucker, MD
The monkeypox outbreak has taken the nation by storm, leading to an increase in diagnostic and vaccination resources. But has this virus prepared us for future infectious disease outbreaks? Joining Dr. Charles Turck to share lessons we’ve learned from the monkeypox outbreak is Dr. Jason Zucker from the Columbia University Irving Medical Center.
Host: Pavani Chalasani MD, MPH
Guest: Hope S. Rugo, MD
Results from the TROPiCS-02 trial may impact survival for patients with receptor–positive/HER2-negative breast cancer. To find out why, Dr. Hope Rugo from the University of California San Francisco Comprehensive Cancer Center joins Dr. Pavani Chalasani to talk about the study and how it might impact the future of breast cancer treatment.
Host: Ayman Al-Hendy, MD
Despite its profound impact, endometriosis remains critically undermanaged. This program provides highlights from a live symposium at the annual meeting for obstetrics and gynecology professionals and is based on patient & provider surveys. Join Dr. Ayman Al-Hendy to explore management gaps, the role of GnRH antagonists in addressing deficits, and the latest research, which he presented with Drs. Andrea Lukes and Lee Shulman—you might just alter your current practice patterns.
Host: Mitchell D. Creinin, MD
In-office delivery of sexual and reproductive healthcare (SRH) services was markedly restricted for 2 years during the COVID-19 pandemic. Now, in-office access to these services has begun to improve. What have we learned since 2020 that can prepare us for future periods of reduced access? Join Dr. Mitchell Creinin as he discusses SRH service strategies initiated during the pandemic that remain useful even in times of full in-office access.
Guest: Gregory Pokrywka MD, FACP, FNLA, FASPC, NCMP
Guest: Karol Watson, MD, PhD
Join us to discover optimal ways to identify women at risk or with atherosclerotic cardiovascular disease (ASCVD). In this Women’s Health 2021 lecture, our experts, Dr. Gregory Pokrywka and Dr. Karol Watson, dive deeper into evidence-based approaches to assess and manage ASCVD in women. They discuss topics from lifestyle modifications to recent clinical trial data on the use of omega-3 fatty acids for ASCVD event reduction.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Dustin Sulak, DO
The medical community continues to voice the medical benefits of cannabis. What do we need to know about them? Dr. Charles Turck discusses the benefits of medical cannabis with Dr. Dustin Sulak, an integrative medicine physician with a special focus on osteopathy, mind-body medicine, and medical cannabis.
Host: Hector O. Chapa, MD, FACOG
ACOG's Annual Clinical and Scientific Meeting will be held virtually this year, but that doesn't mean the content is any less collaborative and impactful. Listen in to hear what ReachMD's host and practicing OB-GYN, Dr. Hector Chapa, is looking forward to at this year's meeting.
Host: Jennifer Caudle, DO
Guest: Tracey Evans, MD
Join Dr. Tracey Evans as she discusses the efficacy data for TAGRISSO® (osimertinib) and the potential impact for metastatic EGFRm NSCLC patients.
In 2018, first-line TAGRISSO became a standard of care for metastatic EGFRm NSCLC with an unprecedented 18.9 months median PFS vs 10.2 months for erlotinib/gefitinib (HR=0.46 [95% CI: 0.37, 0.57]; P<0.0001).1
Now, TAGRISSO is the only EGFR TKI to deliver statistically significant Overall Survival beyond 3 years in a global, phase 3 randomized clinical trial in the first-line setting, (38.6 months vs 31.8 months for erlotinib/gefitinib (HR=0.799 [95.05% CI: 0.641, 0.997]; P=0.0462)).2
Visit TagrissoHCP.com to learn what these data could mean for your patients.
FLAURA study design: Randomized, double-blind, active-controlled trial in 556 patients with metastatic EGFRm NSCLC who had not received prior systemic treatment for advanced disease. Patients were randomized 1:1 to either TAGRISSO (n=279; 80 mg orally, once daily) or EGFR-TKI comparator (n=277; gefitinib 250 mg or erlotinib 150 mg orally, once daily). All US patients in the comparator arm received erlotinib. Crossover was allowed for patients in the EGFR-TKI comparator arm at confirmed progression if positive for the EGFR T790M resistance mutation. Patients with CNS metastases not requiring …
Host: Mario R. Nacinovich, Jr., MSc
Guest: Kara Rood, MD
A recent study following 346 pregnant patients found that 63 percent of the women were admitted into the hospital for uncertain diagnosis or delivery—all because preeclampsia has many of the same symptoms of other diseases. The good news, however, is that there’s a new test currently underway that could make the diagnosis and treatment of preeclampsia easier in order to prevent potentially dangerous outcomes for the mother and baby, as OB/GYN Dr. Kara Rood explains.
Host: Madelaine A. Feldman, MD, FACR
Dr. Marissa Sansone from Jersey City Medical Center-Barnabas Health shares her case study addressing IgG4-related diseases, such as fibroinflammatory disorders, with Dr. Maddie Feldman at this year’s Congress of Clinical Rheumatology’s Annual Meeting.
Host: Alicia A. Sutton
Guest: Camille M. Fung, MD
Host Alicia Sutton is joined by Dr. Camille Fung to discuss two areas of public health in Utah that were not addressed by the Utah legislature: opioid addiction and overdose in pregnant women and newborn infants with Neonatal Abstinence Syndrome (NAS). Dr. Fung is an assistant professor at the University of Utah, Division of Neonatology.
Tune in to see how Dr. Fung with her colleagues created enduring material to educate healthcare professionals on the unaddressed public health problem of opioid management without any financial resources.
The FDA announced that it is requiring a new class warning and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (or MRI) concerning gadolinium remaining in patients’ bodies, including the brain, for months to years after receiving these drugs.
Report side effects involving GBCAs to FDA’s MedWatch program at www.fda.gov/medwatch.
A link to the full communication detailing specific information for health care professionals and a list of FDA approved GBCAs can be found at www.fda.gov/DrugSafety.
Released 12/19/2017